Clinical Trial

Phase 3 Single Arm, Open Study on vYF in Adults

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan. Study details include: * The study duration will be up to approximately 1 month. * One single dose of vYF will be administrated subcutaneously at the 1st visit. * The visit frequency will be Day 01 (Visit 01) and Day 29 (Visit 02). One telephone call (TC) will be planned at Day 15. Number of Participants: A total of 254 participants is expected to be included in the study with the aim to obtain a total of 203 evaluable participants. Study Arms and Duration: Eligible participants will receive, subcutaneously, a single dose of vYF vaccine on Day 1. The duration of each participation will be approximately 1 month for each participant.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-10-27; most recent amendment 2026-02-02.
Status change: Active, Not Recruiting → Completed 2026-02-02
Status change: Recruiting → Active, Not Recruiting 2025-12-02
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT07222059
Lead Sponsor Sanofi Pasteur, a Sanofi Company
Conditions Yellow Fever
Enrollment 254 participants
Start Date 2025-10-23
Primary Completion 2025-12-25 (estimated)
Study Completion 2025-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-02-03